Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.